Objectives:

1.To examine the rationale and trial design of a Phase I trial of a PARP inhibitor, radiation, and immunotherapy in small cell lung cancer

2.To describe cost implications of frontline treatment with combination immunotherapy and chemotherapy for non-small cell lung cancer

3. To discuss a rules-based algorithm to identify patients most in need of advance care planning, as well as implementation of interventions